Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress

por Landsbergen, K. M., Prins, J. B., Brunner, H. G., Hoogerbrugge, N.
Publicado 2010

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI

por Veltman, J., Mann, R., Kok, T., Obdeijn, I. M., Hoogerbrugge, N., Blickman, J. G., Boetes, C.
Publicado 2008

Determinants of adherence to recommendations on physical activity, red and processed meat intake, and body weight among lynch syndrome patients

por Hoedjes, M, Vrieling, A, de Brauwer, L, Visser, A, Gómez García, E, Hoogerbrugge, N, Kampman, E
Publicado 2022

Surveillance of women at high risk for hereditary ovarian cancer is inefficient

por Oei, A L, Massuger, L F, Bulten, J, Ligtenberg, M J, Hoogerbrugge, N, de Hullu, J A
Publicado 2006

Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age

por van Erkelens, A., Derks, L., Sie, A. S., Egbers, L., Woldringh, G., Prins, J. B., Manders, P., Hoogerbrugge, N.
Publicado 2016

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models

por Bodmer, D, Ligtenberg, M J L, van der Hout, A H, Gloudemans, S, Ansink, K, Oosterwijk, J C, Hoogerbrugge, N
Publicado 2006

Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition

por Diets, I J, Nagtegaal, I D, Loeffen, J, de Blaauw, I, Waanders, E, Hoogerbrugge, N, Jongmans, M C J
Publicado 2017

The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery

por Hahn, M. M., de Voer, R. M., Hoogerbrugge, N., Ligtenberg, M. J. L., Kuiper, R. P., van Kessel, A. Geurts
Publicado 2016

Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?

por Oei, A L M, Massuger, L F A G, Bulten, J, Ligtenberg, M J L, Hoogerbrugge, N, de Hullu, J A
Publicado 2006

Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial

por Overbeek, L. I., Hermens, R. P., van Krieken, J. H., Adang, E. M., Casparie, M., Nagengast, F. M., Ligtenberg, M. J., Hoogerbrugge, N.
Publicado 2010

Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist’s initiative

por Landsbergen, K. M., Prins, J. B., Brunner, H. G., van Duijvendijk, P., Nagengast, F. M., van Krieken, J. H., Ligtenberg, M., Hoogerbrugge, N.
Publicado 2012

Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression

por Cleophas, M. C. P., Crişan, T. O., Klück, V., Hoogerbrugge, N., Netea-Maier, R. T., Dinarello, C. A., Netea, M. G., Joosten, L. A. B.
Publicado 2019

Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability

por Kets, C M, van Krieken, J H J M, Hebeda, K M, Wezenberg, S J, Goossens, M, Brunner, H G, Ligtenberg, M J L, Hoogerbrugge, N
Publicado 2006

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

por Koopman, M, Kortman, G A M, Mekenkamp, L, Ligtenberg, M J L, Hoogerbrugge, N, Antonini, N F, Punt, C J A, van Krieken, J H J M
Publicado 2009

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2

por Oldenburg, RA, Kroeze-Jansema, K, Houwing, JJ, Kraan, J, Klijn, JG, Hoogerbrugge, N, Ligtenberg, MJ, van Asperen, CJ, Vasen, HF, Meijers-Heijboer, H, Cornelisse, CJ, Devilee, P
Publicado 2005

Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation

por van Roosmalen, M S, Stalmeier, P F M, Verhoef, L C G, Hoekstra-Weebers, J E H M, Oosterwijk, J C, Hoogerbrugge, N, Moog, U, van Daal, W A J
Publicado 2004

Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers

por van der Post, R S, Kiemeney, L A, Ligtenberg, M J L, Witjes, J A, Hulsbergen-van de Kaa, C A, Bodmer, D, Schaap, L, Kets, C M, van Krieken, J H J M, Hoogerbrugge, N
Publicado 2010

Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer

por Overbeek, L I H, Kets, C M, Hebeda, K M, Bodmer, D, der Looij, E van, Willems, R, Goossens, M, Arts, N, Brunner, H G, van Krieken, J H J M, Hoogerbrugge, N, Ligtenberg, M J L
Publicado 2007

Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers

por Ghorbanoghli, Z., Nieuwenhuis, M. H., Houwing-Duistermaat, J. J., Jagmohan-Changur, S., Hes, F. J., Tops, C. M., Wagner, A., Aalfs, C. M., Verhoef, S., Gómez García, E. B., Sijmons, R. H., Menko, F. H., Letteboer, T. G., Hoogerbrugge, N., van Wezel, T., Vasen, H. F. A., Wijnen, J. T.
Publicado 2016